A Real‐World Study of CAR‐T Hematological Adverse Events Based on FAERS Database.
Chimeric antigen receptor T‐cell therapy (CAR‐T) is an emerging therapy for malignancies, including refractory B‐cell lymphoma, follicular lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Postmarketing monitoring is essential to ensure the rational administration of CAR‐T because of its...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 2025; pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
11/23/2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |